Page last updated: 2024-12-08

clofibride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

clofibride: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID160134
CHEMBL ID1697831
CHEBI ID135401
SCHEMBL ID2091
MeSH IDM0050055

Synonyms (45)

Synonym
4-(dimethylamino)-4-oxobutyl 2-[(4-chlorophenyl)oxy]-2-methylpropanoate
26717-47-5
clofibride
lipenan
clofibride [inn:dcf]
4-chlorophenoxy isopropionyl 4-hydroxy-n,n-dimethylbutyramide
butyramide, n-dimethyl-4-(p-chlorophenoxyisobutyrate)
2-(4-chlorophenoxy)-2-methylpropanoic acid, 4-(dimethylamino)-4-oxobutyl ester
propionic acid, 2-(4-chlorophenoxy)-2-methyl-, 4-(dimethylamino)-4-oxobutyl ester
mg 46
2-(p-chlorophenoxy)-2-methylpropionic acid, ester with 4-hydroxy-n,n-dimethylbutyramide
n-dimethyl-4-(p-chlorophenoxy-1,1'-dimethylacetate)butyramide
clofibridum [inn-latin]
n-dimethyl-4-(1,4'-chlorophenoxyisobutyrate)butyramide
n-dimethyl-4-(p-chlorophenoxyisobutyrate)butyramide
einecs 247-912-7
chloro-4 phenoxyisobutyrate d'hydroxy-4 n-dimethylbutyramide [french]
propionic acid, 2-(p-chlorophenoxy)-2-methyl-, ester with 4-hydroxy-n,n-dimethylbutyramide
n-dimethyl-4-(1,4'-chlorophenoxy-1,1'-dimethylacetate)butyramide
clofibrida [inn-spanish]
brn 2008046
4-hydroxy-n-dimethylbutyramide-4-chlorophenoxy-isobutyrate
D07188
clofibride (inn)
CHEBI:135401
[4-(dimethylamino)-4-oxobutyl] 2-(4-chlorophenoxy)-2-methylpropanoate
CHEMBL1697831
3-(dimethylcarbamoyl)propyl 2-(4-chlorphenoxy)-2-methylpropionat
unii-0s9sls3l93
evimot
clofibridum
0s9sls3l93 ,
clofibrida
chloro-4 phenoxyisobutyrate d'hydroxy-4 n-dimethylbutyramide
clofibride [who-dd]
clofibride [inn]
clofibride [mart.]
SCHEMBL2091
DTXSID1022841
clofibrid
Q4117086
DB13849
CS-0068652
HY-119524
AKOS040751221
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (87.50)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.92 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]